3. Targeted Cancer Therapy: Monoclonal Antibodies and Small-Molecule Anti-Cancer Agents
Outline
- Introduction to Targeted Therapy
- Definitions and History
- Monoclonal Antibodies
- Definition, Discovery
- Mechanism of Action
- Drug Classes
- Antibody-Drug Conjugates
- Small-Molecule Agents
- Definition and History
- Tyrosine Kinase Inhibitors
- Other Small Molecules
- General Approach for APs
- Understanding Targeted Therapies
- Obtaining Consent
- Considerations for Special Populations
After completing this educational activity, participants should be able to:
- Describe the mechanisms of action for common targeted therapies, including monoclonal antibodies and small-molecule targeted agents
- Describe the unique characteristics of common classes of targeted therapies
- Develop an approach for understanding new agents in this rapidly growing field
Jennifer Jacky
MSN, ARNP, AOCNP®
Fred Hutchinson Cancer Center, University of Washington
Ms. Jacky is a is a board-certified oncology nurse practitioner specializing in thoracic and head and neck malignancies. She works as an APP lead at the Fred Hutchinson Cancer Center. Her interests include clinical trials, optimizing symptom control, and primary palliative care.
Jennifer Jacky has no relevant financial relationships to disclose.
Gabrielle Zecha
PA-C, MHA
Fred Hutchinson Cancer Center, University of Washington
Ms. Zecha is a board-certified PA who specializes in the treatment of blood disorders and is the director for the more than 200 advanced practice providers in oncology and stem cell transplant at the Fred Hutchinson Cancer Center and the University of Washington. She has spent her career in oncology in a diverse array of settings, including stem cell transplant, general oncology, and hematologic malignancies.
Gabrielle Zecha has no relevant financial relationships to disclose.